Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Ryan Cross

Senior Science Correspondent

The surfaces of cells are studded with proteins used to communicate with neighbors and visitors. A new method for mapping them and their interactions is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?